Wynn Capital LLC Makes New $455,000 Investment in Biogen Inc. (NASDAQ:BIIB)

Wynn Capital LLC acquired a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,758 shares of the biotechnology company’s stock, valued at approximately $455,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in BIIB. OFI Invest Asset Management bought a new position in shares of Biogen during the 3rd quarter valued at $26,000. Gladius Capital Management LP bought a new position in shares of Biogen during the 3rd quarter valued at $28,000. KB Financial Partners LLC grew its holdings in shares of Biogen by 105.1% during the 3rd quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 62 shares during the last quarter. CVA Family Office LLC bought a new position in shares of Biogen during the 4th quarter valued at $36,000. Finally, Baker Avenue Asset Management LP grew its holdings in Biogen by 215.5% in the 3rd quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Up 4.6 %

NASDAQ:BIIB traded up $8.81 during mid-day trading on Wednesday, reaching $201.99. The company’s stock had a trading volume of 3,264,689 shares, compared to its average volume of 1,191,884. The stock has a market cap of $29.36 billion, a P/E ratio of 25.64, a P/E/G ratio of 1.85 and a beta of -0.02. Biogen Inc. has a twelve month low of $189.44 and a twelve month high of $319.76. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.00 and a quick ratio of 1.26. The company’s fifty day simple moving average is $213.55 and its two-hundred day simple moving average is $234.62.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 EPS for the quarter, missing the consensus estimate of $3.18 by ($0.23). Biogen had a return on equity of 14.91% and a net margin of 11.81%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period last year, the firm posted $4.05 earnings per share. On average, equities analysts predict that Biogen Inc. will post 15.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BIIB shares. JPMorgan Chase & Co. cut their price target on shares of Biogen from $270.00 to $240.00 and set a “neutral” rating on the stock in a report on Thursday, April 11th. HC Wainwright reaffirmed a “buy” rating and issued a $325.00 target price on shares of Biogen in a research report on Wednesday, February 14th. Truist Financial reaffirmed a “buy” rating and issued a $340.00 target price on shares of Biogen in a research report on Monday, March 25th. Wells Fargo & Company cut shares of Biogen from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $315.00 to $240.00 in a research report on Wednesday, February 14th. Finally, StockNews.com cut shares of Biogen from a “buy” rating to a “hold” rating in a research report on Tuesday, February 20th. Ten investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $295.35.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 419 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $239.45, for a total value of $100,329.55. Following the completion of the sale, the insider now owns 4,516 shares in the company, valued at $1,081,356.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Priya Singhal sold 419 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $239.45, for a total transaction of $100,329.55. Following the transaction, the insider now directly owns 4,516 shares of the company’s stock, valued at $1,081,356.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Eric K. Rowinsky bought 455 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was purchased at an average cost of $222.54 per share, for a total transaction of $101,255.70. Following the completion of the transaction, the director now owns 20,629 shares in the company, valued at $4,590,777.66. The disclosure for this purchase can be found here. In the last quarter, insiders sold 882 shares of company stock worth $202,030. 0.60% of the stock is owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.